| 1 | controlled | 73,322 |
| 2 | aldactone | 27 |
| 3 | controled | 15 |
| 4 | norvasc | 9 |
| 5 | contolled | 4 |
| 6 | emmy | 4 |
| 7 | non-masked | 4 |
| 8 | cluster-controlled | 3 |
| 9 | tiv-controlled | 3 |
| 10 | warfarin-controlled | 3 |
| 11 | 9921 | 2 |
| 12 | biomarker-controlled | 2 |
| 13 | clinicals | 2 |
| 14 | clopidogrel-controlled | 2 |
| 15 | control-led | 2 |
| 16 | controlled/clinical | 2 |
| 17 | crossover-controlled | 2 |
| 18 | effect.one | 2 |
| 19 | eortc/lysa/fil | 2 |
| 20 | group.neither | 2 |
| 21 | haemolysis.two | 2 |
| 22 | high-validity | 2 |
| 23 | inappropriate.one | 2 |
| 24 | j-mind | 2 |
| 25 | ofmulticentre | 2 |
| 26 | studies.non-randomised | 2 |
| 27 | 0109 | 1 |
| 28 | 03-2b | 1 |
| 29 | 07-03 | 1 |
| 30 | 11,517 | 1 |
| 31 | 16,106 | 1 |
| 32 | 17,285 | 1 |
| 33 | 3,916 | 1 |
| 34 | 53,742 | 1 |
| 35 | 9902 | 1 |
| 36 | alcohol-treatment-matching | 1 |
| 37 | appliances.one | 1 |
| 38 | arthritis.one | 1 |
| 39 | assignment.five | 1 |
| 40 | bias.neither | 1 |
| 41 | cessation-induction | 1 |
| 42 | clip-1 | 1 |
| 43 | collaboration.thirty-five | 1 |
| 44 | company-independent | 1 |
| 45 | comparison.long-term | 1 |
| 46 | comtrolled | 1 |
| 47 | conrolled | 1 |
| 48 | considered.placebo-controlled | 1 |
| 49 | contro-lled | 1 |
| 50 | control-three | 1 |
| 51 | control/single | 1 |
| 52 | controlld | 1 |
| 53 | controlled-intervention | 1 |
| 54 | controlled/ | 1 |
| 55 | cross-over-designed | 1 |
| 56 | defense-funded | 1 |
| 57 | development.further | 1 |
| 58 | effect'.eight | 1 |
| 59 | efficacy.two | 1 |
| 60 | evidence.more | 1 |
| 61 | experience.the | 1 |
| 62 | glycaemia-controlled | 1 |
| 63 | goirc | 1 |
| 64 | h97-e | 1 |
| 65 | human-intervention | 1 |
| 66 | improvement.ten | 1 |
| 67 | infants-malawi | 1 |
| 68 | interprim | 1 |
| 69 | kilojoule-controlled | 1 |
| 70 | korinna | 1 |
| 71 | larger-controlled | 1 |
| 72 | medico-economics | 1 |
| 73 | model.fifteen | 1 |
| 74 | muticentric | 1 |
| 75 | non-manufacturer-associated | 1 |
| 76 | non-perceived | 1 |
| 77 | nontreatment-controlled | 1 |
| 78 | nut-feeding | 1 |
| 79 | on-off/off-on | 1 |
| 80 | open-lable | 1 |
| 81 | parallel-block | 1 |
| 82 | partner-us | 1 |
| 83 | performance-impairment | 1 |
| 84 | phase-iii-trials | 1 |
| 85 | pill.the | 1 |
| 86 | propective | 1 |
| 87 | randomised-control | 1 |
| 88 | rare-disease | 1 |
| 89 | rfviia.fourteen | 1 |
| 90 | sacramento-emigrant | 1 |
| 91 | same-target | 1 |
| 92 | shoe-lacing | 1 |
| 93 | sinphoni-2 | 1 |
| 94 | smoking-intervention | 1 |
| 95 | stopami | 1 |
| 96 | studies/meta-analysis | 1 |
| 97 | teams.the | 1 |
| 98 | ten-site | 1 |
| 99 | test.two | 1 |
| 100 | tester-blind | 1 |
| 101 | timi-51 | 1 |
| 102 | tolerated.one | 1 |
| 103 | trachoma-ziada | 1 |
| 104 | treatment-strategy | 1 |
| 105 | trials-1 | 1 |
| 106 | trials.future | 1 |
| 107 | trials.in | 1 |
| 108 | uk-evar | 1 |
| 109 | video-endoscopies | 1 |
| 110 | woundssix | 1 |
| 111 | wsg-am-01 | 1 |
| 1 | 0109 | 1 |
| 2 | 03-2b | 1 |
| 3 | 07-03 | 1 |
| 4 | 11,517 | 1 |
| 5 | 16,106 | 1 |
| 6 | 17,285 | 1 |
| 7 | 3,916 | 1 |
| 8 | 53,742 | 1 |
| 9 | 9902 | 1 |
| 10 | 9921 | 2 |
| 11 | alcohol-treatment-matching | 1 |
| 12 | aldactone | 27 |
| 13 | appliances.one | 1 |
| 14 | arthritis.one | 1 |
| 15 | assignment.five | 1 |
| 16 | bias.neither | 1 |
| 17 | biomarker-controlled | 2 |
| 18 | cessation-induction | 1 |
| 19 | clinicals | 2 |
| 20 | clip-1 | 1 |
| 21 | clopidogrel-controlled | 2 |
| 22 | cluster-controlled | 3 |
| 23 | collaboration.thirty-five | 1 |
| 24 | company-independent | 1 |
| 25 | comparison.long-term | 1 |
| 26 | comtrolled | 1 |
| 27 | conrolled | 1 |
| 28 | considered.placebo-controlled | 1 |
| 29 | contolled | 4 |
| 30 | contro-lled | 1 |
| 31 | control-led | 2 |
| 32 | control-three | 1 |
| 33 | control/single | 1 |
| 34 | controled | 15 |
| 35 | controlld | 1 |
| 36 | controlled | 73,322 |
| 37 | controlled-intervention | 1 |
| 38 | controlled/ | 1 |
| 39 | controlled/clinical | 2 |
| 40 | cross-over-designed | 1 |
| 41 | crossover-controlled | 2 |
| 42 | defense-funded | 1 |
| 43 | development.further | 1 |
| 44 | effect'.eight | 1 |
| 45 | effect.one | 2 |
| 46 | efficacy.two | 1 |
| 47 | emmy | 4 |
| 48 | eortc/lysa/fil | 2 |
| 49 | evidence.more | 1 |
| 50 | experience.the | 1 |
| 51 | glycaemia-controlled | 1 |
| 52 | goirc | 1 |
| 53 | group.neither | 2 |
| 54 | h97-e | 1 |
| 55 | haemolysis.two | 2 |
| 56 | high-validity | 2 |
| 57 | human-intervention | 1 |
| 58 | improvement.ten | 1 |
| 59 | inappropriate.one | 2 |
| 60 | infants-malawi | 1 |
| 61 | interprim | 1 |
| 62 | j-mind | 2 |
| 63 | kilojoule-controlled | 1 |
| 64 | korinna | 1 |
| 65 | larger-controlled | 1 |
| 66 | medico-economics | 1 |
| 67 | model.fifteen | 1 |
| 68 | muticentric | 1 |
| 69 | non-manufacturer-associated | 1 |
| 70 | non-masked | 4 |
| 71 | non-perceived | 1 |
| 72 | nontreatment-controlled | 1 |
| 73 | norvasc | 9 |
| 74 | nut-feeding | 1 |
| 75 | ofmulticentre | 2 |
| 76 | on-off/off-on | 1 |
| 77 | open-lable | 1 |
| 78 | parallel-block | 1 |
| 79 | partner-us | 1 |
| 80 | performance-impairment | 1 |
| 81 | phase-iii-trials | 1 |
| 82 | pill.the | 1 |
| 83 | propective | 1 |
| 84 | randomised-control | 1 |
| 85 | rare-disease | 1 |
| 86 | rfviia.fourteen | 1 |
| 87 | sacramento-emigrant | 1 |
| 88 | same-target | 1 |
| 89 | shoe-lacing | 1 |
| 90 | sinphoni-2 | 1 |
| 91 | smoking-intervention | 1 |
| 92 | stopami | 1 |
| 93 | studies.non-randomised | 2 |
| 94 | studies/meta-analysis | 1 |
| 95 | teams.the | 1 |
| 96 | ten-site | 1 |
| 97 | test.two | 1 |
| 98 | tester-blind | 1 |
| 99 | timi-51 | 1 |
| 100 | tiv-controlled | 3 |
| 101 | tolerated.one | 1 |
| 102 | trachoma-ziada | 1 |
| 103 | treatment-strategy | 1 |
| 104 | trials-1 | 1 |
| 105 | trials.future | 1 |
| 106 | trials.in | 1 |
| 107 | uk-evar | 1 |
| 108 | video-endoscopies | 1 |
| 109 | warfarin-controlled | 3 |
| 110 | woundssix | 1 |
| 111 | wsg-am-01 | 1 |
| 1 | controlled/ | 1 |
| 2 | clip-1 | 1 |
| 3 | trials-1 | 1 |
| 4 | wsg-am-01 | 1 |
| 5 | 9921 | 2 |
| 6 | timi-51 | 1 |
| 7 | sinphoni-2 | 1 |
| 8 | 9902 | 1 |
| 9 | 53,742 | 1 |
| 10 | 07-03 | 1 |
| 11 | 17,285 | 1 |
| 12 | 16,106 | 1 |
| 13 | 3,916 | 1 |
| 14 | 11,517 | 1 |
| 15 | 0109 | 1 |
| 16 | trachoma-ziada | 1 |
| 17 | korinna | 1 |
| 18 | 03-2b | 1 |
| 19 | muticentric | 1 |
| 20 | goirc | 1 |
| 21 | norvasc | 9 |
| 22 | defense-funded | 1 |
| 23 | non-masked | 4 |
| 24 | control-led | 2 |
| 25 | contro-lled | 1 |
| 26 | conrolled | 1 |
| 27 | comtrolled | 1 |
| 28 | controlled | 73,322 |
| 29 | glycaemia-controlled | 1 |
| 30 | kilojoule-controlled | 1 |
| 31 | clopidogrel-controlled | 2 |
| 32 | warfarin-controlled | 3 |
| 33 | considered.placebo-controlled | 1 |
| 34 | larger-controlled | 1 |
| 35 | biomarker-controlled | 2 |
| 36 | cluster-controlled | 3 |
| 37 | crossover-controlled | 2 |
| 38 | nontreatment-controlled | 1 |
| 39 | tiv-controlled | 3 |
| 40 | contolled | 4 |
| 41 | controled | 15 |
| 42 | cross-over-designed | 1 |
| 43 | studies.non-randomised | 2 |
| 44 | non-manufacturer-associated | 1 |
| 45 | non-perceived | 1 |
| 46 | controlld | 1 |
| 47 | tester-blind | 1 |
| 48 | j-mind | 2 |
| 49 | h97-e | 1 |
| 50 | control-three | 1 |
| 51 | experience.the | 1 |
| 52 | pill.the | 1 |
| 53 | teams.the | 1 |
| 54 | open-lable | 1 |
| 55 | control/single | 1 |
| 56 | tolerated.one | 1 |
| 57 | inappropriate.one | 2 |
| 58 | appliances.one | 1 |
| 59 | arthritis.one | 1 |
| 60 | effect.one | 2 |
| 61 | aldactone | 27 |
| 62 | evidence.more | 1 |
| 63 | ofmulticentre | 2 |
| 64 | trials.future | 1 |
| 65 | rare-disease | 1 |
| 66 | ten-site | 1 |
| 67 | collaboration.thirty-five | 1 |
| 68 | assignment.five | 1 |
| 69 | propective | 1 |
| 70 | shoe-lacing | 1 |
| 71 | nut-feeding | 1 |
| 72 | alcohol-treatment-matching | 1 |
| 73 | stopami | 1 |
| 74 | infants-malawi | 1 |
| 75 | parallel-block | 1 |
| 76 | controlled/clinical | 2 |
| 77 | eortc/lysa/fil | 2 |
| 78 | randomised-control | 1 |
| 79 | interprim | 1 |
| 80 | comparison.long-term | 1 |
| 81 | model.fifteen | 1 |
| 82 | rfviia.fourteen | 1 |
| 83 | improvement.ten | 1 |
| 84 | trials.in | 1 |
| 85 | on-off/off-on | 1 |
| 86 | cessation-induction | 1 |
| 87 | controlled-intervention | 1 |
| 88 | smoking-intervention | 1 |
| 89 | human-intervention | 1 |
| 90 | haemolysis.two | 2 |
| 91 | test.two | 1 |
| 92 | efficacy.two | 1 |
| 93 | uk-evar | 1 |
| 94 | group.neither | 2 |
| 95 | bias.neither | 1 |
| 96 | development.further | 1 |
| 97 | medico-economics | 1 |
| 98 | video-endoscopies | 1 |
| 99 | studies/meta-analysis | 1 |
| 100 | clinicals | 2 |
| 101 | phase-iii-trials | 1 |
| 102 | partner-us | 1 |
| 103 | same-target | 1 |
| 104 | effect'.eight | 1 |
| 105 | sacramento-emigrant | 1 |
| 106 | company-independent | 1 |
| 107 | performance-impairment | 1 |
| 108 | woundssix | 1 |
| 109 | treatment-strategy | 1 |
| 110 | emmy | 4 |
| 111 | high-validity | 2 |